precisionlife gives us a powerful new way to study and understand complex diseases. It finds unique disease signatures that lead us quickly to the right targets in the right tissues and the right patients, and helps us understand how best to tackle disease.

Dr Véronique Bouchet, MBA
Chief Medical Officer

+44 (0) 1865 575 170
 Office hours 9am - 6pm

AI Enabled Drug Discovery

precisionlife’s drug discovery platform brings together a patented mathematical framework, AI and deep semantic algorithms to mine existing research data. We use these insights to generate new mechanistic explanations of the interactions between genes, metabolic pathways, diseases and drugs.

Dr Steve Gardner
Chief Executive Officer

UK
C9 Glyme Court, Langford Lane
Kidlington, OX5 1LQ

USA
1 Broadway
Cambridge 02142, MA

DENMARK
Agern Allé 3
DK-2970 Hørsholm

POLAND
26 Zurawia St. Loc 10
00-515 Warsaw

Copyright 2018 RowAnalytics Ltd | Read our Privacy Policy | All Rights Reserved

+44 (0) 1865 575 170
 Office hours 9am - 6pm

Steve is a pioneer of healthcare informatics with over 25 years' experience.

He specialises in developing and commercializing novel data science and informatics applications in multiple companies in the US, UK & mainland Europe. He is a former Global Director of Research Informatics for Astra A/B and an Advisory Council member for Breast Cancer Now and UKCRC. He has published over 30 papers and is principal inventor on 24 patents & applications.

Previous events:

GEC+ Taipei 26th-29th September 2018
View Event

MedCity Converge – 11th-12th July 2018
View Event

Precision Medicine Leaders' Summit – 26th-28th June 2018
View Event

BIO International Convention - 4th-7th June 2018
View Event

precisionlife is a radical new approach to complex disease analysis.

Dr Steve Gardner
Chief Executive Officer

•    Multiple novel validated drug targets from existing datasets
•    Targeted drug repurposing opportunities
•    Improved biomarker-driven patient stratification strategies

precisionlife is delivering:

Complex diseases such as oncology, neurodegenerative, psychiatry and cardiometabolic disease don't have simple, single gene explanations. If we want to understand why some patients have higher risk or respond to drugs differently, we need to look deeper.

precisionlife has a unique ability to rapidly find all of the combinations of genomic, phenotypic and clinical features that define disease risk, prognosis and therapy response in a complex disease population. We have proven that these disease signatures can lead us to validated targets, drug discovery opportunities and better personalized medicine.

Meet the precisionlife team at these events:

Bringing together global heads of IT, data, analytics, bioinformatics, computational biology, translational medicine, from leading pharmaceutical companies.
View Event

BioData World, Basel – 28th-29th November 2018
Harnessing the Power of Big Data in Precision Medicine

info@precisionlife.com

info@precisionlife.com

AI Enabled Precision Medicine

Our deeper insights into the structure of disease populations give us a better quantitative understanding the clinical significance of the combination of an individual patient's features. That empowers truly personal precision medicine.

•    Precision medicine clinical decision support tools
•    More precise personalized risk scoring
•    Fully personalized digital health solutions

precisionlife is delivering:

Dr Véronique Bouchet, MBA
Chief Medical Officer

She specialises in bridging the gap from research to commercialisation. She is a former Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca, where she was responsible for AZ’s global corporate venturing activities, including the creation and $40M financing of the company’s first GI spinout, Albireo.

Véronique has over 30 years’ international experience in healthcare.

Patentability, inventorship, ownership and monetisation.
View Event

TIPLO AI Dinner, London – 9th October 2018
Artificial intelligence and drug discovery